Severe earnings deterioration: GAAP EPS guidance cut 11% ($1.51/share) to $12.26, signaling material profit decline that management is masking through adjusted earnings metrics that exclude mounting costs Core business contraction accelerating: Confirmed loss of 425,000 Medicare Advantage members in FY2025 represents significant market share erosion in flagship segment, though management frames…

Our analysis rates this filing BEARISH. The HIGH concern level (7.5/10) reflects multiple material negative developments that signal fundamental business deterioration in Humana's core Medicare Advantage segment. The 11% GAAP EPS guidance cut mid-year is a significant red flag, indicating the…

Concern level: HIGH (7.5/10). Key factors: GAAP EPS guidance slashed 11% mid-year ($1.51 per share reduction to $12.26), indicating material earnings deterioration beyond previous expectations; Confirmed Medicare Advantage membership decline of 425,000 members in core business segment, representing significant market share erosion and revenue loss; Benefit ratio of 91.1% in Q3 with full-year…

Notable risk changes: GAAP EPS guidance slashed 11% ($1.51 per share) to $12.26 from $13.77 - material earnings deterioration beyond previous expectations, though Adjusted EPS guidance maintained at $17.00 through exclusions; Medicare Advantage membership decline of 425,000 members confirmed for FY 2025, representing significant market share loss in core business despite being 'better than expected' versus prior…

The model predicts HUM will outperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.